{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:32:55Z","timestamp":1772890375730,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Project of Education Department of Guizhou Province","award":["050100406"],"award-info":[{"award-number":["050100406"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejphar.2018.07.049","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T12:17:49Z","timestamp":1532693869000},"page":"64-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Bevacizumab with dose-dense paclitaxel\/carboplatin as first-line chemotherapy for advanced ovarian cancer"],"prefix":"10.1016","volume":"837","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.07.049_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies\u2013a review","volume":"8","author":"Al-Abd","year":"2017","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.ejphar.2018.07.049_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib3","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/IGC.0b013e3181e94331","article-title":"A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma","volume":"20","author":"Brown","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib4","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib5","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib6","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","author":"Cannistra","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib7","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib8","unstructured":"Chan, J., Brady, M., Penson, R., Monk, B., Boente, M., Walker, J., Davidson, S., DiSilvestro, P., O'Malley, D., Morgan, M., 2013. PHASE III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin plus\/-bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262 (NCT01167712). International Journal of Gynecological Cancer. LIppincott Williams & Wilkins 530 Walnut ST, Philadelphia, PA 19106-3621 USA."},{"key":"10.1016\/j.ejphar.2018.07.049_bib9","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ygyno.2009.03.018","article-title":"Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm","volume":"114","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib11","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1002\/ijc.30676","article-title":"International patterns and trends in ovarian cancer incidence, overall and by histologic subtype","volume":"140","author":"Coburn","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib12","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2018.07.049_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0092-8674(94)90187-2","article-title":"The implications of angiogenesis for the biology and therapy of cancer metastasis","volume":"79","author":"Fidler","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2018.07.049_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2017.07.137","article-title":"Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer","author":"Fleming","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib18","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s40064-016-2660-0","article-title":"Management of relapsed ovarian cancer: a review","volume":"5","author":"Giornelli","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.ejphar.2018.07.049_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ygyno.2015.03.049","article-title":"Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care","volume":"137","author":"G\u00f3mez-Hidalgo","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib20","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1016\/j.ejca.2013.08.002","article-title":"Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer","volume":"49","author":"Gonzalez-Martin","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib21","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","article-title":"Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks","volume":"23","author":"Green","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/cam4.376","article-title":"Paclitaxel\/carboplatin with or without sorafenib in the first\u2010line treatment of patients with stage III\/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute","volume":"4","author":"Hainsworth","year":"2015","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib23","first-page":"6744","article-title":"Differential gene expression between normal and tumor-derived ovarian epithelial cells","volume":"60","author":"Ismail","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.049_bib24","first-page":"e201606840","article-title":"VEGFA activates an epigenetic pathway upregulating ovarian cancer\u2010initiating cells","author":"Jang","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ejphar.2018.07.049_bib26","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib27","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.07.049_bib28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.07.049_bib29","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1525-1438.2007.00886.x","article-title":"A phase II study of outpatient first\u2010line paclitaxel, carboplatin, and bevacizumab for advanced\u2010stage epithelial ovarian, peritoneal, and fallopian tube cancer","volume":"17","author":"Micha","year":"2007","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib30","first-page":"255","article-title":"Can advanced-stage ovarian cancer be cured? Nature reviews","volume":"13","author":"Narod","year":"2016","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib32","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib33","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.03.036","article-title":"Cancer stem cells: recent developments and future prospects","volume":"338","author":"Singh","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2018.07.049_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2010.03.018","article-title":"The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab","volume":"118","author":"Smerdel","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.049_bib36","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer","volume":"358","author":"Sparano","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.049_bib37","first-page":"3369","article-title":"The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors","volume":"61","author":"Sweeney","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.049_bib38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","author":"Thall","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.ejphar.2018.07.049_bib39","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/sj.bjc.6601005","article-title":"Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11","volume":"88","author":"Wildiers","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.049_bib40","doi-asserted-by":"crossref","first-page":"10703","DOI":"10.18632\/oncotarget.12926","article-title":"Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304266?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304266?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T17:03:51Z","timestamp":1604682231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918304266"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":40,"alternative-id":["S0014299918304266"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.049","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab with dose-dense paclitaxel\/carboplatin as first-line chemotherapy for advanced ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}